Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
We aim at identifying potential biomarkers in plasma indicative of post-acute coronavirus SARS-CoV-2 Syndrome (Long COVID). Our case-control study will compare Long COVID patients to healthy patients from Sutter Health.
Two measures will be obtained from participants' plasma:
The diagnostic utility of the potential biomarkers, including signatures derived from microbial cell-free DNA fragments found in plasma and plasma cytokines, will be evaluated independently and in various combinations to determine whether and to what extent we can accurately identify Long COVID patients. Moreover, we plan to leverage the Karius Test and the underlying Karius microbial cell-free DNA technology to determine whether there is evidence of more frequent reactivations of latent infections in patients with long COVID compared to matched healthy control. Plasma samples will also be stored for future comparative studies of additional immune profiles.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Long COVID Subjects | Long COVID patients with a duration of illness longer than 6 months or longer will be included in the study. | ||
| Healthy Controls | Healthy controls, matched by age to a long COVID subject (+/-10 years and preferably by sex). |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Metagenomics | In this proof-of-concept study, we want to test the hypothesis that mcfDNA has diagnostic utility as a biomarker for long COVID patients by applying the agnostic metagenomic sequencing approach. | Baseline |
| Cytokines | Cytokine signatures have been associated with disease severity in patients with chronic fatigue syndrome (Montoya et al, Proc Natl Acad Sci U S A. 2017 Aug 22;114(34): E7150-E7158.). We want to test the hypothesis that cytokine profiles may serve as surrogate biomarkers for Long COVID. | Baseline |
| Metadata analysis | Analysis of microbial-cell-free DNA and cytokine to identity meta-signatures associated with Long COVID and/or Long COVID severity. | Baseline |
Not provided
Not provided
Inclusion Criteria:
≥ 18-year-old
English speaking (per Sutter medical records information)
Ability and willingness to provide signed Consent Form
Ability to comply with the study protocol
Ability to attend the study visit, complete questionnaires, have blood collected and tested And, either Long-COVID or Healthy control as described below
Long-COVID patient Cohort (n=75)
Sutter patient who is a patient from Sutter Health Holistic/Integrative Medicine clinic
Documentation of a long-COVID diagnosis (U09.9) for patient's initial visit in clinic between 01/01/2021 and 06/30/2024.
Presence of active and ongoing long-COVID symptoms
Ongoing long-COVID symptoms consistently present over the previous 6 months or longer
Presence of the following long-COVID symptoms (a, b, and c plus either d or e) affecting you more than 50% of your life:
Healthy controls with no Long COVID syndrome (n=75)
Exclusion Criteria:
Pregnant or nursing woman
Alcohol or another drug abuse ongoing within one year
Severe depression or acute suicidal ideation
Bipolar disorder, schizophrenia, or other psychosis
History of malignancy, except basal cell carcinoma
History of significant autoimmune disorder:
Active pulmonary infection (active pneumonia)
Chronic kidney disease
Chronic liver disease
Chronic lung disease
Pulmonary fibrosis
Interstitial pneumonitis
Uncontrolled asthma
Chronic obstructive pulmonary disease (COPD)
Reactive arthritis
Immunocompromised conditions or weaken immune system:
Biologicals impacting the immune system
Taking immunosuppressor
Neurologic conditions:
Heart conditions:
Not provided
Not provided
Not provided
Not provided
This study will focus on participants with a diagnosis code for long-COVID (U09.9) in their Sutter EMR and healthy controls who are Sutter Health's patients.
It will enroll 75 patients diagnosed with long-COVID and 75 matched healthy controls respectively.
Healthy controls will be matched 1:1 to long-COVID patients for age (+/-10 years and preferably by sex).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jose G Montoya | Sutter Health, Palo Alto Medical Foundation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sutter Health Palo Alto Center | Palo Alto | California | 94301 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000094024 | Post-Acute COVID-19 Syndrome |
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Plasma samples will also be stored for future comparative studies of additional immune profiles.
| D007239 |
| Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |